Skip to main content
Article thumbnail
Location of Repository

Viral and murine interleukin-10 are correctly processed and retain their biological activity when produced in tobacco

By Luisa Bortesi, Marzia Rossato, Flora Schuster, Nicole Raven, Johannes Stadlmann, Linda Avesani, Alberto Falorni, Flavia Bazzoni, Ralph Bock, Stefan Schillberg and Mario Pezzotti
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2667500
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (1994). A C, Faye L: Distribution of xylosylation and fucosylation in the plant Golgi-apparatus. Plant J
    2. (2006). A KDEL-tagged monoclonal antibody is efficiently retained in the endoplasmic reticulum in leaves, but is both partially secreted and sorted to protein storage vacuoles in seeds.
    3. (2001). A self-contained system for the field production of plant recombinant interleukin-10. Molecular Breeding
    4. (1999). A: Interleukin10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood
    5. (2007). Aberrant localization and underglycosylation of highly accumulating single-chain Fv-Fc antibodies in transgenic Arabidopsis seeds. Proc Natl Acad Sci USA
    6. (2000). Altmann F: N-glycan analysis by matrix-assisted laser desorption/ionization mass spectrometry of electrophoretically separated nonmammalian proteins: application to peanut allergen Ara h 1 and olive pollen allergen Ole e 1. Anal Biochem
    7. (2004). AM: Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4. Proc Natl Acad Sci USA
    8. (2007). AM: Therapeutic effectiveness of orally administered transgenic low-alkaloid tobacco expressing human interleukin-10 in a mouse model of colitis.
    9. (1997). Angenon G: An Agrobacterium-mediated transient gene expression system for intact leaves. Plant Science
    10. (2007). Approaches to achieve high-level heterologous protein production in plants.
    11. (2000). Arntzen CJ: Plants for delivery of edible vaccines. Curr Opin Biotechnol
    12. (2002). Bazzoni F: Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharideinduced macrophage activation.
    13. (2004). Brunak S: Improved prediction of signal peptides:
    14. (2001). Cassatella MA: Up-regulation of IL-10R1 expression is required to render human neutrophils fully responsive to IL-10. J Immunol
    15. (1998). Compartment-specific accumulation of recombinant immunoglobulins in plant cells: an essential tool for antibody production and immunomodulation of physiological functions and pathogen activity. Plant Mol Biol
    16. (1993). Cytokine structural taxonomy and mechanisms of receptor engagement.
    17. (1991). de Vries JE: Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.
    18. (2007). Elastinlike polypeptide fusions enhance the accumulation of recombinant proteins in tobacco leaves. Transgenic Res
    19. (1999). Finbloom DS: Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1. Blood
    20. (1998). G o m o r d V , F a y e L : N-glycoprotein biosynthesis in plants: recent developments and future trends. Plant Mol Biol
    21. (2000). Gomord V: Protein recycling from the Golgi apparatus to the endoplasmic reticulum in plants and its minor contribution to calreticulin retention. Plant Cell
    22. (2000). Groux H: Can interleukin-10 be used as a true immunoregulatory cytokine? Eur Cytokine Netw
    23. (2002). High level expression and purification of the Epstein-Barr virus encoded cytokine viral interleukin 10: efficient removal of endotoxin. Cytokine
    24. (2003). Ito A: Dual subcellular distribution of cytochrome b5 in plant, cauliflower, cells. J Biochem (Tokyo)
    25. (1992). Ito A: The carboxy-terminal 10 amino acid residues of cytochrome b5 are necessary for its targeting to the endoplasmic reticulum. Embo J
    26. (2002). JL: Suppression of autoimmune diabetes by viral IL10 gene transfer.
    27. (2000). JS: A single amino acid determines the immunostimulatory activity of interleukin 10. J Exp Med
    28. (1990). KW: Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science
    29. (1998). Langridge WH: Efficacy of a food plantbased oral cholera toxin B subunit vaccine. Nat Biotechnol
    30. (2004). Lerouge P: Recombinant anti-hCG antibodies retained in the endoplasmic reticulum of transformed plants lack corexylose and core-alpha(1,3)-fucose residues.
    31. (2007). Locating proteins in the cell using TargetP, SignalP and related tools. Nat Protoc
    32. (2005). Molecular farming for new drugs and vaccines. Current perspectives on the production of pharmaceuticals in transgenic plants. EMBO Rep
    33. (2003). Molecular farming in plants: host systems and expression technology. Trends Biotechnol
    34. (1990). Mosmann TR: Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI.
    35. (2005). MR: Same structure, different function crystal structure of the Epstein-Barr virus IL10 bound to the soluble IL-10R1 chain. Structure
    36. (1990). MW: Isolation of monoclonal antibodies specific for IL4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay.
    37. (1991). O'Garra A: IL10 inhibits cytokine production by activated macrophages.
    38. (2008). Pedrazzini E: Anchorage to the cytosolic face of the endoplasmic reticulum membrane: a new strategy to stabilize a cytosolic recombinant antigen in plants.
    39. (2005). Pedrazzini E: Recombinant pharmaceuticals from plants: the plant endomembrane system as bioreactor. Mol Interv
    40. (2000). Plasma membrane display of anti-viral single chain Fv fragments confers resistance to tobacco mosaic virus. Molecular Breeding
    41. (1999). Saturation of the endoplasmic reticulum retention machinery reveals anterograde bulk flow. Plant Cell
    42. (1996). Schots A, et al.: The C-terminal KDEL sequence increases the expression level of a single-chain antibody designed to be targeted to both the cytosol and the secretory pathway in transgenic tobacco. Plant Mol Biol
    43. (2004). Secreted immunomodulatory viral proteins as novel biotherapeutics.
    44. (2004). Subcellular targeting of human interleukin-10 in plants.
    45. (2006). Sunderasan E: Structural analysis of the glycoprotein allergen Hev b 4 from natural rubber latex by mass spectrometry. Biochim Biophys Acta
    46. (2007). T: Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures.
    47. (1997). The C-terminal HDEL sequence is sufficient for retention of secretory proteins in the endoplasmic reticulum (ER) but promotes vacuolar targeting of proteins that escape the ER. Plant J
    48. (1986). The promoter of TL-DNA gene 5 controls the tissue-specific expression of chimeric genes carried by a novel type of Agrobacterium binary vector. Mol Gen Genet
    49. (1983). Ti-plasmid vector for introduction of DNA into plant cells without altering their normal regeneration capacity. Embo J
    50. (2005). Transgenic plants in the biopharmaceutical market. Expert Opin Emerg Drugs
    51. (2008). U: Biochemical and functional characterization of anti-HIV antibody-ELP fusion proteins from transgenic plants. Plant Biotechnol J
    52. (2001). Vitale A: Influence of KDEL on the fate of trimeric or assembly-defective phaseolin: selective use of an alternative route to vacuoles. Plant Cell
    53. (2003). Volk HD: Interleukin-10 therapy – review of a new approach. Pharmacol Rev
    54. (1997). Wlodawer A: Crystal structure of Epstein-Barr virus protein BCRF1, a homolog of cellular interleukin-10.
    55. (1995). Wlodawer A: Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma. Structure

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.